Biogen’s Tecfidera Hit At NICE By Data Shortage, Functional Unblinding
This article was originally published in The Pink Sheet Daily
Executive Summary
NICE has demanded more data and analyses for Biogen Idec’s MS champion, Tecfidera, before it clears a drug expected to be a worthy opponent for Novartis’ Gilenya.